Literature DB >> 11161387

Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.

V M Tut1, K L Braithwaite, B Angus, D E Neal, J Lunec, J K Mellon.   

Abstract

Normal cell proliferation is closely regulated by proteins called cyclins. One of these, cyclin D1, in combination with its corresponding cyclin-dependent kinase (cdk), is essential for G(1)/S phase transition. Cyclin/cdk complexes are generally inhibited by cyclin-dependent kinase inhibitors(ckis), some of which are induced by wild-type p53. The aims of this study were: to investigate levels of cyclin D1 expression in transitional cell carcinoma (TCC) of the bladder; to correlate these results with data concerning the expression of p53, waf1, pRb and Ki67; and to determine whether cyclin D1 expression could predict clinical outcome. Paraffin-sections from 150 newly diagnosed bladder tumours (Ta/T1 = 97; T2-T4 = 53) were stained for cyclin D1 using immunohistochemistry and a cyclin D1 index assigned. These results were correlated with data relating to the expression of p53 and waf1 by the same tumours. A representative subset of 54 tumours (Ta/T1 = 28; T2-T4 = 26) was also stained for Ki67 and 55 were stained for pRb. The clinical course of each patient was recorded and multivariate analyses of risk factors for tumour recurrence, stage progression and overall survival were performed. Positive staining for cyclin D1 was found in 83% of tumours. The staining pattern varied between tumours with nuclear, cytoplasmic or a combination of the two evident in different tumours. 89% of Ta/T1 and 74% of T2-T4 tumours showed nuclear staining with or without cytoplasmic staining. The median value for cyclin D1 staining was significantly higher in Ta/T1 tumours (41%) compared with T2-T4 tumours (8%, P< 0.005) with 26% of muscle-invasive tumours demonstrating absent staining. In addition, the median value for cyclin D1 staining was significantly higher in G1/G2 tumours (43%) compared with G3 tumours (14%, P< 0.005). There was a significant positive correlation between expression of cyclin D1 and waf1 expression (P< 0.0001) as well as pRb expression but not between cyclin D1 expression and expression of p53. Ki67 expression was significantly associated with increasing tumour stage (P< 0.005) and histological grade (P< 0.05) but did not correlate with cyclin D1 expression. A cyclin D1 index > or = 8% was associated with significantly better survival in those patients with muscle-invasive disease (T2-T4). In addition, there was a significantly higher progression rate for those patients with Ta/T1 disease whose tumours demonstrated cytoplasmic cyclin D1 staining. These results indicate that cyclin D1 expression is significantly higher in low-stage, well differentiated bladder tumours and strongly correlates with waf1 expression. In a multivariate analysis, cyclin D1 expression is an independent prognostic indicator of survival in those patients with muscle-invasive disease. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161387      PMCID: PMC2363716          DOI: 10.1054/bjoc.2000.1557

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element.

Authors:  J A DeCaprio; J W Ludlow; D Lynch; Y Furukawa; J Griffin; H Piwnica-Worms; C M Huang; D M Livingston
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

Review 2.  G1 phase progression: cycling on cue.

Authors:  C J Sherr
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

Review 3.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

4.  Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines.

Authors:  J Lukas; M Pagano; Z Staskova; G Draetta; J Bartek
Journal:  Oncogene       Date:  1994-03       Impact factor: 9.867

5.  Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.

Authors:  E Schuuring; E Verhoeven; W J Mooi; R J Michalides
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

6.  Cyclin D1 expression is regulated by the retinoblastoma protein.

Authors:  H Müller; J Lukas; A Schneider; P Warthoe; J Bartek; M Eilers; M Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  p21-containing cyclin kinases exist in both active and inactive states.

Authors:  H Zhang; G J Hannon; D Beach
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

8.  Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts.

Authors:  M Pagano; A M Theodoras; S W Tam; G F Draetta
Journal:  Genes Dev       Date:  1994-07-15       Impact factor: 11.361

9.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Authors:  C Gillett; V Fantl; R Smith; C Fisher; J Bartek; C Dickson; D Barnes; G Peters
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes.

Authors:  V Dulić; L F Drullinger; E Lees; S I Reed; G H Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more
  20 in total

1.  Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China.

Authors:  Rui-Jue Wang; Lin-Jie Lu; Liang-Bin Jin; Hong-Yuan Li; Guo-Sheng Ren; Kai-Nan Wu; Sheng-Chun Liu; Ling-Quan Kong
Journal:  Med Oncol       Date:  2013-12-12       Impact factor: 3.064

Review 2.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer.

Authors:  Fabia Galmozzi; Alessandra Rubagotti; Andrea Romagnoli; Giorgio Carmignani; Luisa Perdelli; Beatrice Gatteschi; Francesco Boccardo
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-21       Impact factor: 4.553

4.  Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.

Authors:  Saba El-Gendi; Ghada Abu-Sheasha
Journal:  Pathol Oncol Res       Date:  2017-05-09       Impact factor: 3.201

Review 5.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

6.  Expression of Cyclin D1 Is Associated with β-Catenin Expression and Correlates with Good Prognosis in Colorectal Adenocarcinoma.

Authors:  Kyu Yun Jang; Yo Na Kim; Jun Sang Bae; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Dong Geun Lee; Ho Sung Park
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 7.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

8.  Cyclin D1 immunoreactivity in meningiomas.

Authors:  Sanja Milenković; Tatjana Marinkovic; Milan B Jovanovic; Slavisa Djuricic; Ivana I Berisavac; Iva Berisavac
Journal:  Cell Mol Neurobiol       Date:  2008-04-01       Impact factor: 5.046

9.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

10.  Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models.

Authors:  Aleksandar Janev; Taja Železnik Ramuta; Larisa Tratnjek; Žiga Sardoč; Hristina Obradović; Slavko Mojsilović; Milena Taskovska; Tomaž Smrkolj; Mateja Erdani Kreft
Journal:  Front Bioeng Biotechnol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.